Journal of Surgery Concepts & Practice ›› 2019, Vol. 24 ›› Issue (05): 406-411.doi: 10.16139/j.1007-9610.2019.05.008
• Experts forum • Previous Articles Next Articles
Received:2019-07-08
Online:2019-10-05
Published:2019-10-05
CLC Number:
| [1] Ellisen LW, Haber DA, Hereditary breast cancer[J]. Annu Rev Med,1998,49:425-436. [2] Nielsen FC, van Overeen Hansen T, Sørensen CS. Hereditary breast and ovarian cancer: new genes in confined pathways[J]. Nat Rev Cancer,2016,16(9):599-612. [3] Stratton MR, Rahman N.The emerging landscape of breast cancer susceptibility[J]. Nat Genet,2008,40(1):17-22. [4] Foulkes WD.Inherited susceptibility to common cancers[J]. N Engl J Med,2008,359(20):2143-2153. [5] Weitzel JN, Blazer KR, MacDonald DJ, et al. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine[J]. CA Cancer J Clin,2011,61(5):327-359. [6] Chen S, Parmigiani G.Meta-analysis of BRCA1 and BRCA2 penetrance[J]. J Clin Oncol,2007,25(11):1329-1333. [7] Yao L, Sun J, Zhang J, et al.Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations[J]. Breast Cancer Res Treat,2016,156(3):441-445. [8] Sun J, Meng H, Yao L, et al.Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients[J]. Clin Cancer Res,2017,23(20):6113-6119. [9] Valachis A, Nearchou AD, Lind P.Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis[J]. Breast Cancer Res Treat,2014,144(3):443-455. [10] Cao W, Xie Y, He Y, et al.Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China[J]. Breast Cancer Res Treat,2019, 175(3):749-754. [11] Beitsch PD, Whitworth PW, Hughes K, et al.Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle?[J]. J Clin Oncol,2019,37(6):453-460. [12] Grindedal EM, Heramb C, Karsrud I, et al.Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers[J]. BMC Cancer,2017,17(1):438. [13] Knerr S, Bowles EJA, Leppig KA, et al.Trends in BRCA test utilization in an integrated health system, 2005-2015[J]. J Natl Cancer Inst,2019,111(8):795-802 [14] US Preventive Services Task Force, Owens DK, Davidson KW, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force Recommendation Statement[J]. JAMA,2019,322(7):652-665. [15] Gross AL, Blot WJ, Visvanathan K.BRCA1 and BRCA2 testing in medically underserved medicare beneficiaries with breast or ovarian cancer[J]. JAMA,2018,320(6):597-598. [16] Kurian AW, Griffith KA, Hamilton AS, et al.Genetic testing and counseling among patients with newly diagnosed breast cancer[J]. JAMA,2017,317(5):531-534. [17] Modaffari P, Ponzone R, Ferrari A, et al. Concerns and expectations of risk-reducing surgery in women with hereditary breast and ovarian cancer syndrome[J]. J Clin Med,2019,8(3). pii: E313. [18] Gill Jr, Obley AJ, Prasad V.Direct-to-consumer genetic testing: The implications of the US FDA's first marketing authorization for BRCA mutation testing[J]. JAMA,2018, 319(23):2377-2378. [19] Tran SD, Pillemer SR, Dutra A, et al.Differentiation of human bone marrow-derived cells into buccal epithelial cells in vivo: a molecular analytical study[J]. Lancet,2003,361(9363):1084-1088. [20] NCCN. Genetic/Familial High-Risk Assessment: Breast and Ovarian. (Version 2.2019) [EB/OL]. [2019-07-03]. https://www.nccn.org/professionals/physician_gls/pdf/genetics_sc-reening.pdf [21] Golubeva VA, Nepomuceno TC, Monteiro ANA. Germline missense variants in BRCA1: New trends and challenges for clinical annotation[J]. Cancers (Basel),2019,11(4).pii: E522. [22] 《BRCA数据解读中国专家共识》编写组. BRCA数据解读中国专家共识[J]. 中华病理学杂志,2017,46(5):293-297. [23] Findlay GM, Daza RM, Martin B, et al.Accurate classification of BRCA1 variants with saturation genome editing[J]. Nature,2018,562(7726):217-222. [24] Cline MS, Liao RG, Parsons MT, et al.BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2[J]. PLoS Genet,2018,14(12):e1007752. [25] Spurdle AB, Healey S, Devereau A, et al.ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes[J]. Hum Mutat,2012, 33(1):2-7. [26] King MC, Wieand S, Hale K, et al.Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial[J]. JAMA,2001,286(18):2251-2256. [27] Nolan E, Vaillant F, Branstetter D, et al.RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers[J]. Nat Med,2016,22(2):933-939. [28] Narod SA, Lubinski J, Ghadirian P, et al.Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study[J]. Lancet Oncol,2006,7(5):402-406. [29] Plevritis SK, Kurian AW, Sigal BM, et al.Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging[J]. JAMA,2006,295(20):2374-2384. [30] Saadatmand S, Geuzinge HA, Rutgers EJT, et al.MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial[J]. Lancet Oncol,20(8):1136-1147. [31] Carbine NE, Lostumbo L, Wallace J, et al. Risk-reducing mastectomy for the prevention of primary breast cancer[J]. Cochrane Database Syst Rev,2018,4(1):CD002748. [32] Contant CM, Menke-Pluijmers MB, Seynaeve C, et al.Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation[J]. Eur J Surg Oncol,2002,28(6):627-632. [33] 中国医师协会精准治疗委员会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组,中国抗癌协会乳腺癌专业委员会. 中国乳腺癌患者BRCA1/2基因检测与临床应用专家共识(2018年版)[J]. 中国癌症杂志,2018,28(10):787-800. [34] Pierce LJ, Levin AM, Rebbeck TR, et al.Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage Ⅰ/Ⅱ breast cancer[J]. J Clin Oncol,2006,24(16):2437-2443. [35] Terry MB, Daly MB, Phillips KA, et al.Risk-reducing ophorectomy and breast cancer risk across the spectrum of familial risk[J]. J Natl Cancer Inst,2019,111(3):331-334. [36] Wang H, Xiang D, Liu B, et al.Inadequate DNA damage repair promotes mammary transdifferentiation, leading to BRCA1 breast cancer[J]. Cell,2019,178(1):135-151. [37] Tutt A, Tovey H, Cheang MCU, et al.Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial[J]. Nat Med,2018,24(5):628-637. [38] Hahnen E, Lederer B, Hauke J, et al.Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial[J]. JAMA Oncol,2017,3(10):1378-1385. [39] Robson M, Im SA, Senkus E, et al.Olaparib for metastatic breast cancer in patients with a germline BRCA mutatio[J]. N Engl J Med,2017,377(6):523-533. [40] Cruz C, Llop-Guevara A, Garber JE, et al.Multicenter phase Ⅱ study of lurbinectedin in BRCA-mutated and unselected metastatic advanced breast cancer and biomarker assessment substudy[J]. J Clin Oncol,2018,36(31):3134-3143. [41] Castro E, Goh C, Olmos D, et al.Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer[J]. J Clin Oncol,2013,31(14):1748-1757. [42] Baretta Z, Mocellin S, Goldin E, et al.Effect of BRCA germline mutations on breast cancer prognosis: A syste matic review and meta-analysis[J]. Medicine (Baltimore),2016,95(40):e4975. [43] Copson ER, Maishman TC, Tapper WJ, et al.Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study[J]. Lancet Oncol,2018,19(2):169-180. [44] Deng M, Chen HH, Zhu X, et al.Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China[J]. Int J Cancer,2019,145(6):1517-1528. [45] Terry MB, Liao Y, Whittemore AS, et al.10-year performance of four models of breast cancer risk: a validation study[J]. Lancet Oncol,2019,20(4):504-517. |
| [1] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 385-386. |
| [2] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 387-391. |
| [3] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 392-395. |
| [4] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 396-402. |
| [5] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 403-405. |
| [6] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 406-410. |
| [7] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 411-415. |
| [8] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 416-420. |
| [9] | YANG Cuiyan, WANG Haoyu, CHEN Xiaosong, SHEN Kunwei. Study on tumour suppressor gene TP53 mutation and prognosis in patients with triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 421-428. |
| [10] | PAN Ruixin, CHEN Xiaosong, SHEN Kunwei. Study on circulating tumor DNA and circulating tumor cell detecting minimal residual disease in breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 463-467. |
| [11] | ZHU Siyi, CHEN Xiaosong, SHEN Kunwei. Study on obesity associated with prognosis of early breast cancer and efficacy of adjuvant therapy [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 468-472. |
| [12] | WANG Jieqiang, MA Dekui. Study on trophoblast cell-surface antigen 2 gene and triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 473-477. |
| [13] | LIU Miao, SHEN Yan, FU Xiaohong, HU Jiaojiao, CHEN Qingqing, YING Tao. A comparative study on breast cancer between smaller and larger diameters using conventional ultrasound and contrast-enhanced ultrasound [J]. Journal of Surgery Concepts & Practice, 2022, 27(3): 229-233. |
| [14] | CHEN Yuanyuan, YE Xin, TANG Yongzhe, WANG Jie, HE Qi. Prognosis of invasive micropapillary carcinoma versus invasive ductal carcinoma of the breast: a comparative analysis after propensity score matching [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 353-360. |
| [15] | CHEN Xiaosong, LI Shuai, WU Jiayi, HUANG Ou, CHAI Weimin, YAO Jiejie, ZHU Ying, XU Chen, CHEN Jiayi, QU Qing, FEI Xiaochun, DING Xiaoyi, LIN Lin, ZHANG Nan, FANG Qiong, HE Jianrong, ZHU Li, LI Yafen, CHEN Weiguo, SHEN Kunwei. Diagnosis, treatment and survival of breast cancer patients in single large hospital: a 10-year analysis [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 149-158. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
